All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

GSK's Exdensur (depemokimab) wins FDA approval for severe eosinophilic asthma treatment following Ph3 trials
Antibody, autoimmune, monoclonal antibody, severe asthma, eosinophilic phenotype, IL-5 pathway - Read more

THE GOOD
Business Development & Partnerships

MapLight Therapeutics, SandboxAQ partner on CNS drug discovery targeting novel GPCR, $200M milestones
Research collaboration, neurological, AI/ML, drug discovery, milestone payments - Read more

Genentech, Caris Life Sciences collaborate on AI-driven cancer target discovery, $25M upfront, $1.1B milestones
Research collaboration, oncology, AI/ML, milestone payments - Read more

Yarrow Bioscience, GenSci partner on autoimmune thyroid disease drug GS-098, $70M upfront, $1.37B total
Licensing deal, autoimmune, antibody, milestone payments - Read more

Fosun Pharma acquires 53% stake in Green Valley Pharmaceuticals for $200M, reviving Alzheimer's drug GV-971
Acquisition, neurological, drug discovery, equity investment - Read more

Lindus Health, Quotient Sciences partner to accelerate drug development through integrated clinical trial services
Strategic partnership, clinical trials, patient recruitment, drug development, R&D - Read more

Lunit, Daiichi Sankyo collaborate on AI pathology tools for two oncology R&D programs
Research collaboration, oncology, AI/ML, digital health - Read more

RoslinCT, Ayrmid expand partnership for Omisirge commercial manufacturing following second FDA approval
Manufacturing agreement, cell therapy, hematology, commercial supply - Read more

Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for $315M
Royalty acquisition, oncology, small molecule, tyrosine kinase inhibitors - Read more

PRESENTED BY SCIENCE 2 SALES
Cold calling in the life sciences - free webinar!

By popular demand, we’re running two webinars on cold calling in the life sciences - same session but two different times for convenience!

We’ll be covering:
• Why cold calling is so powerful right now (hint: points at all the AI everywhere)
• What is (and isn't) cold calling
• When it's worth it (sometimes it's not!)
• Mindset, strategies, and the technical bits behind doing cold calling

And probably a bunch more things - also a special guest 👀

Email [email protected] to get your invite

✅ More Good News ✅

THE GOOD
Clinical Trials

DBV Technologies' Viaskin Peanut meets Ph3 VITESSE trial primary endpoint for peanut allergy treatment
Protein therapy, autoimmune, epicutaneous immunotherapy, peanut allergy, desensitization - Read more

OrsoBio's TLC-6740 combination with tirzepatide shows positive Ph1b/2a results for obesity treatment
Small molecule, metabolic, mitochondrial protonophore, obesity, combination therapy, GLP-1 receptor agonist - Read more

Monte Rosa Therapeutics reports positive Ph1/2 data for MRT-2359 targeting GSPT1 in metastatic castration-resistant prostate cancer
Small molecule, cancer, molecular glue degrader, metastatic castration-resistant prostate cancer, combination therapy - Read more

Nektar Therapeutics plans Ph3 trial for rezpegaldesleukin targeting interleukin-2 in severe alopecia areata after Ph2 success
Protein therapy, autoimmune, interleukin-2 targeting, alopecia areata, phase 3 planning - Read more

THE GOOD
Company Launches

Ambros Therapeutics launches with $125M Series A to advance Italian non-opioid pain drug neridronate
Bisphosphonate, pain management, strategic, major transaction - Read more

Link Cell Therapies debuts with $60M series A from J&J, BMS for logic-gated CAR-T platform
CAR-T, oncology, strategic, major transaction - Read more

THE GOOD
Fundraises

Allink Biotherapeutics raises $47M Series A extension, advancing ADC clinical programs
Oncology, antibody-drug conjugates, clinical-stage, multi-specific antibody, solid tumors - Read more

Aeovian Pharmaceuticals raises $55M Series B, funding Phase II epilepsy study
Neurological, rare disease, small molecule, clinical-stage - Read more

TargED Biopharmaceuticals raises €21.5M ($25.3M) Series A extension for thrombotic disease treatments
Thrombotic diseases, clinical-stage, targeted therapeutics, first-in-class - Read more

THE GOOD
Regulatory

NICE appoints Jonathan Benger as new CEO ahead of expanded NHS mandate implementation
Regulatory, strategic, operational, financial - Read more

FDA Commissioner Makary denies plans for black box warning on COVID-19 vaccines, contradicting CNN report
mRNA vaccine, infectious disease, regulatory, operational - Read more

THE GOOD
Strategic Plans

Pfizer plans 15 obesity trials next year to replace $17 billion patent cliff revenue loss
Small molecule, obesity, strategic, major transaction, patent cliff, revenue impact - Read more [Paywall]

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Hansa Biopharma's imlifidase misses primary endpoint in Ph3 trial for anti-glomerular basement membrane disease
Protein therapy, autoimmune, enzyme therapy, anti-GBM disease, IgG-degrading enzyme, kidney transplant - Read more

THE BAD
Company Shutdown

Mythic Therapeutics shuts down, terminates lung cancer ADC trial after failing to secure funding
Antibody-drug conjugate, oncology, operational, financial - Read more [Paywall]

THE BAD
Earnings & Finances

Pfizer forecasts 2026 sales of $59.5-62.5B amid declining COVID products and patent losses
mRNA vaccine, infectious disease, financial, revenue impact - Read more

THE BAD
Regulatory

Novo Nordisk receives FDA warning letter for contamination issues at Indiana manufacturing facility
Biologic manufacturing, regulatory, operational, manufacturing quality - Read more

FDA extends Aldeyra Therapeutics' reproxalap (RASP modulator) dry eye disease review deadline to March
Small molecule, ophthalmology, dry eye disease, RASP modulator - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here